We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
The current BIO market cap is 819.13M. The company's latest EPS is EUR 6.3388 and P/E is 6.50.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Revenue | 419.1M | 484.2M | 515.6M | 516.1M | 684.6M |
| Operating Income | 1.8M | -1.8M | -45.8M | -17.7M | 146.2M |
| Net Income | -5.49M | -32.19M | -64.19M | -31.7M | 125.42M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Assets | 1.11B | 1.13B | 1.1B | 1.2B | 1.41B |
| Total Liabilities | 631.5M | 689.7M | 723.8M | 831.9M | 912M |
| Total Equity | 476.9M | 441.6M | 380.4M | 371.1M | 498.9M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Operating | -33.6M | -16.7M | 33.9M | -40.5M | -2.7M |
| Investing | -8M | -14.6M | -23.4M | -37M | 1.3M |
| Financing | 40.5M | 42M | 22.6M | 89.6M | -6.8M |
| Market Cap | 819.13M |
| Price to Earnings Ratio | 6.50 |
| Price to Sales Ratio | 1.19 |
| Price to Cash Ratio | 7.54 |
| Price to Book Ratio | 1.63 |
| Dividend Yield | - |
| Shares Outstanding | 19.79M |
| Average Volume (1 week) | 48 |
| Average Volume (1 Month) | 36 |
| 52 Week Change | -1.90% |
| 52 Week High | 44.60 |
| 52 Week Low | 39.40 |
| Spread (Intraday) | 0.6 (1.44%) |
| Company Name | Biotest AG |
| Address |
landsteinerstrasse 5 dreieich 63303 |
| Website | https://www.biotest.de |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
